Related Experiment Video

Updated: Feb 28, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.8K

The regulatory role of DPP4 in atherosclerotic disease

Lihua Duan1,2, Xiaoquan Rao2, Chang Xia2,3

  • 1Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, Fujian, China.

Cardiovascular Diabetology
|June 17, 2017
PubMed

Insights

Dipeptidyl peptidase-4 (DPP4) may play a role in atherosclerosis development and progression. This review summarizes DPP4

Area of Science:

  • Cardiovascular Science
  • Metabolic Disease Research
  • Immunology and Inflammation Studies

Background:

  • Atherosclerosis is a growing global health issue with incompletely understood mechanisms.
  • Dipeptidyl peptidase-4 (DPP4), a key regulator of inflammation and metabolism, is increasingly implicated in atherosclerotic diseases.
  • The DPP4-incretin axis shows emerging links to cardiovascular disease, prompting further investigation.

Purpose of the Study:

  • To review recent findings on the direct and indirect roles of DPP4 in atherosclerosis.
  • To consolidate current understanding of DPP4's involvement in the pathogenesis of atherosclerotic diseases.

Main Methods:

  • Literature review of recent clinical and pre-clinical studies.
  • Analysis of research on DPP4 inhibition and incretin analogues in cardiovascular outcomes.
  • Synthesis of evidence regarding DPP4's regulatory functions in atherosclerosis.

Main Results:

  • DPP4 influences inflammation and metabolism, key factors in atherosclerosis.
  • Evidence suggests the DPP4-incretin axis impacts cardiovascular health.
  • Ongoing clinical trials are evaluating DPP4 inhibition's cardiovascular effects.

Conclusions:

  • DPP4's precise role in atherosclerotic diseases requires further elucidation.
  • Understanding DPP4's regulatory functions is crucial for developing novel therapeutic strategies.
  • Further research is needed to fully clarify DPP4's complex involvement in atherosclerosis.
Keywords:
AtherosclerosisDPP4 inhibitorDipeptidyl peptidaseGliptinsIncretin

More Related Videos

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.6K

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
490
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
520
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.6K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
787
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
817
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K